COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,620 Articles (22,913 medRxiv, 8,707 bioRxiv)

Most recent first Previous |  Page 1526: Articles 15251-15260  | Next

Estimating the SARS-CoV-2 infected population fraction and the infection to-fatality ratio: A data-driven case study based on Swedish time series data
Wacker, A., Jöud, A., Bernhardsson, B., Gerlee, P., Gustafsson, F., Soltesz, K.
10.1101/2021.05.27.21257900 — Posted: 2021-05-31
The rapid reemergence of seasonal respiratory viruses in Houston, Texas, after relaxing COVID-19 restrictions
Hodjat, P., Christensen, P., Subedi, S., Olsen, R. J., Bernard, D. W., Long, S. W.
10.1101/2021.05.27.21257940 — Posted: 2021-05-30
Antibody Display of cell surface receptor Tetraspanin12 and SARS-CoV-2 spike protein
Hsieh, F.-L., Chang, T.-H.
10.1101/2021.05.29.446300 — Posted: 2021-05-30
Human genome integration of SARS-CoV-2 contradicted by long-read sequencing
Smits, N., Rasmussen, J., Bodea, G. O., Amarilla, A. A., Gerdes, P., Sanchez-Luque, F. J., Ajjikuttira, P., Modhiran, N., Liang, B., Faivre, J., Deveson, I. W., Khromykh, A. A., Watterson, D., Ewing, A. D., Faulkner, G. J.
10.1101/2021.05.28.446065 — Posted: 2021-05-30 Discussion: Onsite
Computational genomic analysis of the lung tissue microenvironment in COVID-19 patients
Bhuvaneshwar, K., Madhavan, S., Gusev, Y.
10.1101/2021.05.28.446250 — Posted: 2021-05-30
Amyloidogenic proteins in the SARS-CoV and SARS-CoV-2 proteomes
Bhardwaj, T., Gadhave, K., Kapuganti, S. K., Kumar, P., Brotzakis, Z. F., Saumya, K. U., Nayak, N., Kumar, A., Garg, N., Vendruscolo, M., Giri, R.
10.1101/2021.05.29.446267 — Posted: 2021-05-30
Broadening a SARS-CoV-1 neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution
Zhao, F., Yuan, M., Keating, C., Shabaani, N., Limbo, O., Joyce, C., Woehl, J., Barman, S., Burns, A., Zhu, X., Ricciardi, M., Peng, L., Smith, J., Huang, D., Briney, B., Sok, D., Nemazee, D., Teiijaro, J., Wilson, I. A., Burton, D., Jardine, J. G.
10.1101/2021.05.29.443900 — Posted: 2021-05-30
Corowa-kun: Impact of a COVID-19 vaccine information chatbot on vaccine hesitancy, Japan 2021
Kobayashi, T., Nishina, Y., Tomoi, H., Harada, K., Tanaka, K., Matsumoto, E., Horimukai, K., Ishihara, J., Sasaki, S., Inaba, K., Seguchi, K., Takahashi, H., Salinas, J., Yamada, Y.
10.1101/2021.05.26.21257854 — Posted: 2021-05-30
MALDI-ToF Protein Profiling as Potential Rapid Diagnostic Platform for COVID-19
Chivte, P., LaCasse, Z., Seethi, V. D. R., Bharti, P., Gaillard, E. R.
10.1101/2021.05.26.21257798 — Posted: 2021-05-30
Clinical Evaluation of In House Produced 3D Printed Nasopharyngeal Swabs for COVID-19 Testing
Grandjean Lapierre, S., Bedwani, S., Deblois, F., Fortin, A., Zamorano Cuervo, N., Zerouali, K., Caron, E., Morency Potvin, P., Gagnon, S., Nguissan, N., Arlotto, P., Hardy, I., Boutin, C.-A., Tremblay, C., Coutlee, F., de Guise, J., Grandvaux, N.
10.1101/2021.05.26.21257548 — Posted: 2021-05-30

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).